Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis.
Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.
Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis.
Has evidence of active, noninfectious pneumonitis that requires treatment with steroids
Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
History of (noninfectious) pneumonitis that require steroids or current pneumonitis
Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis.
Evidence of interstitial lung disease or noninfectious pneumonitis.
Has evidence of active, noninfectious pneumonitis that required treatment with steroids
Has known history of or any evidence of active, noninfectious pneumonitis
Known history of, or any evidence of, interstitial lung disease or active noninfectious pneumonitis
History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.
Patients who have evidence of active, noninfectious pneumonitis or have a history of severe pneumonitis that required treatment with steroids are not eligible for this study
Has known history of, or any evidence of active, noninfectious pneumonitis
Patients with a history of noninfectious pneumonitis will be excluded during the dose-escalation phase of the trial
Patient has history of interstitial lung disease or known history of, or any evidence of active, noninfectious pneumonitis
Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
DOSE ESCALATION COHORT: Evidence of or any history of interstitial lung disease or active, noninfectious pneumonitis including symptomatic and/or pneumonitis requiring treatment
DOSE EXPANSION COHORT: Evidence of or any history of interstitial lung disease or active, noninfectious pneumonitis including symptomatic and/or pneumonitis requiring treatment
Evidence of interstitial lung disease or active, noninfectious pneumonitis
Has evidence of noninfectious pneumonitis that required steroids or current pneumonitis.
Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
History of (noninfectious) pneumonitis that required steroids or current pneumonitis.
Has evidence or history of interstitial lung disease or active noninfectious pneumonitis
Evidence of active noninfectious pneumonitis or history of interstitial lung disease.
Patients who have evidence of active, noninfectious pneumonitis or have a history of severe pneumonitis that required treatment with steroids are not eligible for this study; (Note: replacement physiologic dose of steroids [prednisone 10 mg daily or equivalent] are allowed)
History of (noninfectious) pneumonitis that required steroids or current pneumonitis
Patients with interstitial lung disease or active, noninfectious pneumonitis
History of noninfectious pneumonitis
Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
History or evidence of active, noninfectious pneumonitis that required treatment with steroids
EXCLUSION CRITERIA FOR CROSSOVER THERAPY: History or evidence of active, noninfectious pneumonitis that required treatment with steroids
Known history of, or any evidence of, interstitial lung disease or active noninfectious pneumonitis.
Patients must not have a history of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, noninfectious pneumonitis